Genentech Diabetic Macular Oedema Drug Meets Primary Endpoint

Study results showed that diabetic macular oedema patients who were treated with Lucentis experienced rapid and sustained improvement.

Genentech has reported positive two-year results from a pivotal Phase III trial evaluating the efficacy and safety of Lucentis (ranibizumab injection) in patients with diabetic macular oedema. A significantly greater number of patients who received Lucentis were able to read at least 15 additional letters on an eye chart compared to baseline after 24 months, which was the primary endpoint.

The study results showed that diabetic macular oedema patients who were treated with Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.

A significant improvement was seen in average eye chart reading scores at 24 months and even as early as seven days.